Humboldt Fund

Metagenomi Therapeutics is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The Company was founded on the science of metagenomics, the study of genetic materials recovered from the natural environment, to discover and develop a suite of novel editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome.

Finch Therapeutics is a pioneer in the microbiome therapeutics field, focusing on innovative microbiome assets with potential applications across various therapeutic areas. The company has a robust intellectual property estate and is developing therapeutics aimed at conditions such as recurrent C. difficile infection, ulcerative colitis, Crohn’s disease, and autism spectrum disorder.

Leading DNA Synthesis Company that manufactures synthetic DNA, overcoming limitations of traditional methods to empower scientists in health and sustainability.

Miroculus provides automated solutions for next-generation sequencing (NGS) sample preparation and offers a range of pipetting tools and robots to streamline laboratory workflows.

Geltor is transforming biodesign into a new paradigm for sustainable, ethically sourced, and effective protein ingredients, focusing on beauty, wellness, and nutrition.

Brightseed is a continuous innovation platform that transforms how health science teams discover, validate, and bring new products to market, leveraging deep science and AI to enhance decision-making.

Meatable is a company focused on producing real meat through scientific innovation, aiming to transform the meat industry with sustainable practices.

Mission Barns is a food technology company focused on cultivating meat products without harming animals, aiming to create a more sustainable food system.

MycoWorks is a biotechnology company that specializes in creating sustainable materials from mycelium, a natural and abundant resource. Their flagship product, Reishi™, is engineered using Fine Mycelium™, offering a premium alternative to traditional animal leathers.

Debut Biotech is a pioneering biotech beauty company that creates high-performing beauty products rooted in science and clinical testing, utilizing bio-based ingredients and advanced biomanufacturing techniques.

Concerto Biosciences is focused on creating safe, effective microbial products for human health, leveraging deep ecological insights and advanced AI technologies to develop innovative solutions for skincare, chronic diseases, and nutrition.

Founded by Bryan Johnson, invests in platforms and enabling technologies supporting inventors and scientists building programmable-biology solutions to rewrite life's operating systems and benefit humanity. OS Fund believes biology is programmable, and invests in platforms and enabling technologies (i.e. Ginkgo Bioworks).

Bioscience investor translating grant-funded research into venture-scale companies, with a pipeline centered on engineering biology using robotic cloud labs and computational design for human health and planetary sustainability. The firm grew directly out of a philanthropic grants program at the Thiel Foundation that funded highly speculative science before spinning into a traditional venture fund.

Writes first institutional checks ($500k–$5M) at earliest stages for compute-applied chemistry and biology ventures (therapeutics, industrial biotech, climate, materials), led by an advanced-degree scientific team.

Early-stage accelerator for synthetic biology and life sciences that gives scientist-founders lab independence with co-located BSL-rated wet labs and extended runway via SOSV integration reserving 75% for follow-ons. The world's first startup accelerator focused specifically on synthetic biology and life sciences, created to give scientists independence as founders rather than forcing them into traditional academic or big-pharma tracks. The program runs its own large wet-lab infrastructure where portfolio companies co-locate and build in BSL-rated labs owned by the fund, while providing an unusually long runway of capital through deep integration with SOSV's fund structure that reserves 75% for follow-on rounds.

Flagship Pioneering operates as an "institutional innovation" model that internally originates 80-100 "explorations" per year through Flagship Labs based on "What if…?" hypotheses, then systematically evolves promising ideas through a staged company-creation funnel (Explorations → ProtoCos → NewCos → GrowthCos) that it fully founds, funds, and owns through early stages. The firm positions itself as principal founder rather than a traditional investor, building "bioplatform" companies organized around proprietary discovery engines and operating its own drug development unit, Pioneering Medicines, which partners directly with large pharmas like Pfizer and Novo Nordisk to co-create therapeutics.